

Brand Name	Common Uses	Manufacturer	2003 U.S. Retail Sales (millions)	Anticipated Patent Expiration*	
				Period	Year
Biaxin	Infection	Abbott	\$235	2nd Quarter	2005
Amaryl	Diabetes	Aventis	\$227	2nd Quarter	2005
Zithromax	Infection	Pfizer	\$1,717	4th Quarter	2005
Pravachol	High Cholesterol	Bristol-Myers Squibb	\$1,680	2nd Quarter	2006
Zocor	High Cholesterol	Merck	\$3,329	2nd Quarter	2006
Zoloft	Depression	Pfizer	\$2,531	2nd Quarter	2006
Ambien	Insomnia	Sanofi-Synthelabo	\$1,506	4th Quarter	2006
Lamisil	Nail Fungal Infections	Novartis	\$611	4th Quarter	2006
Allegra and Allegra D	Allergies	Aventis	\$1,859	4th Quarter	2006
Zofran	Nausea	GlaxoSmithKline	\$577	-	2006
Prevacid	GERD, Peptic Ulcers	TAP	\$3,529	1st Quarter	2007
Imitrex	Migraine Headache	GlaxoSmithKline	\$1,092	3rd Quarter	2007
Zytrec and Zyrtec D	Allergies	Pfizer	\$1,440	3rd Quarter	2007
Fosamax, Fosamax Weekly and Fosamax Plus D	Osteoporosis	Merck	\$90	1st Quarter	2008
Depakene and Depakote	Seizures	Abbott	\$689	-	2008
Effexor and Effexor XR	Depression	Wyeth	\$2,090	2nd Quarter	2008
Topamax	Migraines, Seizures	Ortho-McNeil	\$909	3rd Quarter	2008

* Anticipated patent expiration dates are subject to change as a result of litigation, pediatric or other exclusivities, etc.

Sources:

FDA, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book) - *via on-line resources*
FDC Reports, 'The Pink Sheet' - 2004-2005